FDA approves Chembio’s dual path platform HIV-syphilis testing system

Chembio Logo

The FDA approved Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) HIV-syphilis system, a 15-minute test designed to detect HIV Type 1 and 2 antibodies and the bacteria that causes syphilis.

The system includes the DPP HIV-syphilis assay, a multiplex single-use test, and the DPP micro reader optical analyzer. Under the FDA premarket approval, the system is approved for use by trained professionals in point-of-care and laboratory settings to aid in the diagnosis of HIV and syphilis infections.

“The multiplex DPP HIV-syphilis system represents a significant step forward in rapid testing for sexually transmitted diseases,” Rick Emberly, Chembio’s CEO, said in a statement.

“This differentiated test provides clinicians with actionable information to improve patient care in critical areas, including co-infection and mother to child transmission,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.